Skip to main content

Beneficial ownership — 13D / 13G

87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
DENSO Corporation BZAI Blaize Holdings, Inc. 13G/A 0% 6mo
JONATHAN H. DORFMAN QVCAQ QVC Group, Inc. 13G 5.15% 6mo
Fourthstone LLC FMBM F&M Bank Corp 13G/A 9.98% 6mo
WP XI Partners, L.P. SHC Sotera Health Co 13G/A 0% 6mo
Extract Advisors LLC NEXM NexMetals Mining Corp. 13G/A 5.4% 6mo
MILLENNIUM MANAGEMENT LLC FTH Faeth Therapeutics, Inc. 13G 9.6% 6mo
Samsara BioCapital, L.P. STRO Sutro Biopharma, Inc. 13G 6.4% 6mo
John D. Halpern ERNA Ernexa Therapeutics Inc. 13G/A 5.6% 6mo
Freebird Partners LP ERNA Ernexa Therapeutics Inc. 13G/A 9.9% 6mo
Brian Matthew Bloom MSLE Satellos Bioscience Inc. 13G 7.35% 6mo
Sumitomo Mitsui Banking Corporation PSNY Polestar Automotive Holding UK PLC 13G 7.1% 6mo
RP Investment Advisors LP BIII Black Spade Acquisition III Co 13G/A 8.3% 6mo
Nathan Leight ALOV Aldabra 4 Liquidity Opportunity Vehicle, Inc. 13G 19.8% 6mo
IAN T BOTHWELL ZEOX Zeo ScientifiX, Inc. 13D/A 14.7% 6mo
Aquamarine Financial (Cayman) Ltd ORMP Oramed Pharmaceuticals Inc. 13G 5.06% 6mo
Divisadero Street Capital Management, LP SGHC Super Group (SGHC) Ltd 13G 6.1% 6mo
Saturn V Capital Management LP MNPR Monopar Therapeutics 13G 5.2% 6mo
BROWN ADVISORY INC ESTA Establishment Labs Holdings Inc. 13G/A 5.38% 6mo
Fund 1 Investments, LLC SFIX Stitch Fix, Inc. 13G/A 1.62% 6mo
Lynx1 Capital Management LP ALLO Allogene Therapeutics, Inc. 13G/A 0% 6mo
Anson Funds Management LP REKR Rekor Systems, Inc. 13G/A 4.9% 6mo
Driehaus Capital Management LLC XENE Xenon Pharmaceuticals Inc. 13G/A 4.87% 6mo
Pomeroy Scott XTIA XTI Aerospace, Inc. 13D 6.26% 6mo
Anson Funds Management LP VLOS Velos Acquisition I Corp. 13G/A 0.2% 6mo
ALTA FOX OPPORTUNITIES FUND, LP XPEL XPEL, Inc. 13G/A 7% 6mo
Rubric Capital Management LP EDSA Edesa Biotech, Inc. 13G 7.74% 6mo
G1 Execution Services, LLC CORZ Core Scientific, Inc. 13G/A 4.6% 6mo
G1 Execution Services, LLC COIN Coinbase Global, Inc. 13G/A 4.2% 6mo
He Zhengxu CYH Community Health Systems Inc 13G 5.3% 6mo
Leviticus Partners LP UEIC Universal Electronics Inc 13G/A 4.9% 6mo
BIOGEN INC. APLS Apellis Pharmaceuticals, Inc. 13D/A 0% 6mo
Mink Brook Asset Management LLC CHRN ChronoScale Holdings Corp 13G/A 0% 6mo
Deerfield Management Company, L.P. INSP Inspire Medical Systems, Inc. 13G/A 4.5% 6mo
Saba Capital Management, L.P. ASA ASA Gold & Precious Metals Ltd 13D/A 31.91% 6mo
Alexandra Seros EVC Entravision Communications Corp 13D/A 12.18% 6mo
North Run Strategic Opportunities Fund I, LP LPTH Lightpath Technologies Inc 13D/A 14.7% 6mo
RIVER & MERCANTILE ASSET MANAGEMENT LLP MXCT Maxcyte, Inc. 13D 6.1% 6mo
Harraden Circle Investments, LLC CAEP Cantor Equity Partners III, Inc. 13G 14.25% 6mo
Monex Group, Inc. CNCK Coincheck Group N.V. 13D/A 83.6% 6mo
BCLS II Investco, LP NAMS NewAmsterdam Pharma Co N.V. 13D/A 0.1% 6mo
Ramaswamy Vivek BZFD BuzzFeed, Inc. 13D 0% 6mo
Avoro Capital Advisors LLC WHWK Whitehawk Therapeutics, Inc. 13D/A 19.99% 6mo
Redmile Group, LLC ATRA Atara Biotherapeutics, Inc. 13D/A 9.9% 6mo
8 Rivers Capital, LLC NPWR Net Power Inc. 13D/A 19.5% 6mo
ICAHN CARL C JBLU Jetblue Airways Corp 13D/A 6.72% 6mo
BML Investment Partners, L.P. ENGN enGene Therapeutics Inc. 13G/A 9.95% 6mo
David A. Lorber PFX PhenixFIN Corp 13D/A 12.9% 6mo
Cerberus Capital Management II, L.P. EOSE Eos Energy Enterprises, Inc. 13D/A 32% 6mo
RA CAPITAL MANAGEMENT, L.P. HOWL Werewolf Therapeutics, Inc. 13D/A 12.6% 6mo
STARTEEPO Invest, investicni fond s promennym zakladnim kapitalem, a.s. XRX Xerox Holdings Corp 13D 3.98% 6mo